ELAN: Elanco Animal Health Incorporated Stock

by  •  • Comments Off on ELAN: Elanco Animal Health Incorporated Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 6,428.33
Enterprise Value ($M) 11,850.33
Book Value ($M) 6,223.00
Book Value / Share 12.62
Price / Book 1.03
NCAV ($M) -4,732.00
NCAV / Share -9.60
Price / NCAV -1.36

Profitability (mra)
Return on Invested Capital (ROIC) -0.10
Return on Assets (ROA) -0.08
Return on Equity (ROE) -0.16

Liquidity (mrq)
Quick Ratio 1.35
Current Ratio 2.75

Balance Sheet (mrq) ($M)
Current Assets 3,407.00
Assets 14,362.00
Liabilities 8,139.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 4,417.00
Operating Income 328.00
Net Income -1,231.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 271.00
Cash from Investing -169.00
Cash from Financing -83.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Dodge & Cox 17.00 -0.94
02-13 13G/A Vanguard Group Inc 10.04 0.33
02-12 13G/A Primecap Management Co/ca/ 10.27 -0.06
01-29 13G BlackRock Inc. 5.60 15.20

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-38661 Elan
2023-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 418,652 2,926,319 14.31
2024-04-25 368,056 3,247,831 11.33
2024-04-24 362,550 3,812,138 9.51
2024-04-23 709,029 4,785,032 14.82
2024-04-22 586,241 5,395,858 10.86

(click for more detail)

Similar Companies
BMY – Bristol-Myers Squibb Company CTLT – Catalent, Inc.
EBS – Emergent BioSolutions Inc. HYAC – Haymaker Acquisition Corp. 4
JNJ – Johnson & Johnson


Financial data and stock pages provided by
Fintel.io